Moleculin Biotech says AACR pancreatic cancer conference features new Annamycin trial data

Reuters2026/09/14 12:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moleculin Biotech announced new Annamycin data will be presented at three scientific meetings in September 2026.
Two presentations already scheduled in Poland focus on where Annamycin concentrates in the body and how it attacks cancer cells.
An AACR pancreatic cancer presentation is set for Sept. 25-28, with results to be disclosed when the abstract publishes Sept. 25.
Preclinical findings support activity in pancreatic cancer, including signs the drug may help recruit immune cell killing.
The update broadens the program’s potential beyond AML as Moleculin continues its MIRACLE trial of AnnAraC in relapsed or refractory AML.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140835PRIMZONEFULLFEED9826132) on September 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Moleculin Biotech says AACR pancreatic cancer conference features new Annamycin trial data

You may also like

Crypto prices